BHH member Onalabs, a company focused on the development of non-invasive remote wearable solutions for healthcare and sport, have opened a financing round with CapitalCell to get the funds to complete the development of their first two products, one for the chronic patients / home hospitalization remote monitoring and the device to manage athletes’ performance.

In the area of healthcare, Onalabs pipeline is as follows:

• Wearable device addressed to chronic patients and hospital at home patients for the remote monitoring of several vital signs, such as HR, skin T, SpO2, BP and respiratory rate, besides activity and falls. The device – through the Onalabs’ cloud AI platform – will be connected to the public or private IT healthcare systems. It will be a homecare bracelet. Regulatory approval expected by the end of 2022.
• Diabetes patch for the remote, continuous, and non-invasive glucose monitoring through the sweat. The patch will be an add-on to the homecare bracelet or work autonomously. The device will be addressed to type 1 and type 2 diabetic patients and pregnant women with gestational diabetes as well. This project is at an earlier stage and regulatory approval is expected in 2024.

In sports medicine, Onalabs is to finish the development of the device for the remote and non-invasive lactate monitoring through the sweat, the key biomarker for muscle performance. The device will also monitor the HR and the sweat rate. Other functionalities will be added later on. The device will be ready for launching in Q2 2022.

Interested? Read more here!